stockportfolio.pro
Agios Pharmaceuticals, Inc. (AGIO)
Healthcare · Biotechnology · NasdaqGS
Agios Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.89M | $43.01M | $94.39M | $117.91M | $0 | $0 | $14.24M | $26.82M | $36.50M | $54.03M |
| Gross profit | — | — | $92.99M | $116.59M | — | — | $12.54M | $23.94M | $32.33M | $47.68M |
| Net income | $-198.47M | $-314.67M | $-346.03M | $-411.47M | $-327.37M | $1.60B | $-231.80M | $-352.09M | $673.73M | $-412.78M |
| Net margin | -284.0% | -731.6% | -366.6% | -349.0% | — | — | -1627.8% | -1312.6% | 1845.9% | -764.0% |
Source: Agios Pharmaceuticals, Inc. SEC filings (10-K). 15 years of history available in the interactive view.
Explore 15 years of Agios Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AGIO in your portfolio →
Agios Pharmaceuticals, Inc. financial history by metric
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals, Inc. — frequently asked questions
What is Agios Pharmaceuticals, Inc.'s revenue?
Agios Pharmaceuticals, Inc. (AGIO) reported revenue of $54.03M for fiscal year 2025, up 48.0% from the prior year, according to its SEC filings.
Is Agios Pharmaceuticals, Inc. profitable?
No — AGIO reported a net loss of $-412.78M in fiscal 2025.
What is AGIO's P/E ratio?
Agios Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Agios Pharmaceuticals, Inc. have?
As of fiscal year 2025, AGIO carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Agios Pharmaceuticals, Inc.'s gross margin?
AGIO's gross margin was 88.3% in fiscal 2025 — gross profit of $47.68M on revenue of $54.03M.
What is Agios Pharmaceuticals, Inc.'s market cap?
Agios Pharmaceuticals, Inc. (AGIO) has a market capitalization of about $1.70B, based on the latest data in our nightly-refreshed cache.
When does Agios Pharmaceuticals, Inc.'s fiscal year end?
AGIO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Agios Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.